Skip to search formSkip to main contentSkip to account menu

IB1001

Known as: IB1001 trenacog alfa 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Recombinant Proteinsfactor IX

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Patient-Reported Outcomes in Hemophilia B Patients Treated with IB1001 [Coagulation Factor IX (recombinant)]
INTRODUCTION. Hemophilia B is a rare bleeding disorder caused by missing or defective factor IX, a clotting protein in the… 
2012
2012
IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.
Abstract 2225 Introduction IB1001 is a recombinant factor IX product being investigated for the treatment and prevention of… 
2011
2011
Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis
Abstract 2267[][1] Introduction IB1001 is an investigational recombinant factor IX for the treatment and prevention of bleeding… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)